
The inflammation in major depressive disorder (MDD) permeates several states of the disease and is involved in treatment-resistant depression (TRD), among other conditions (Beurel et al., 2020;Chamberlain et al., 2019). In chronic systemic inflammation, altered biological processes can impair the blood-brain barrier (BBB) . Chronic dysregulation of the immune system, with increased release of inflammatory cytokines, affects the BBB and the central nervous system (CNS), altering several neurophysiological mechanisms that can culminate in MDD and other psychiatric disorders (Beurel et al., 2020;Mancuso et al., 2023). Among the altered neurophysiological mechanisms, it is possible to highlight oxidative balance, dysregulation of neurotransmitter release and function, neuronal signaling pathways, and metabolic pathways, such as the kynurenine pathway, among others, which impair the structure and function of brain regions involved in mood regulation (Mancuso et al., 2023;Bertollo et al., 2024). Research has been highlighting that these altered mechanisms from inflammation can lead to MDD or aggravate depressive conditions, culminating in TRD (Beurel et al., 2020). This special research topic includes studies that combine original research and literature reviews, as well as a clinical trial, highlighting several crucial biological mechanisms and psychological factors related to the inflammatory process in depression.Several contributions focus on the molecular and cellular mechanisms linking inflammatory processes to depressive symptomatology. Emerging evidence highlights oxidative stress, inflammasome activation, mitochondrial dysfunction, and alterations in lipid metabolism as key biological pathways that promote neuroinflammation and disrupt neural circuits involved in mood regulation. Together, these studies support the concept that depression arises from complex interactions among metabolic, immune, and neurobiological systems. /full presented a randomized, double-blind, placebo-controlled clinical trial evaluating low-dose naltrexone as an adjunctive treatment for major depressive disorder. Although the intervention did not show significant benefits over placebo, the study provides valuable clinical evidence for ongoing investigations of immunomodulatory strategies in depression and highlights the importance of developing more targeted approaches to neuroinflammation-based treatments.
The present collection of studies consolidates the view that MDD and TRD arise from complex interactions among metabolic, immune, and neurobiological systems. Chronic immune dysregulation and excessive release of inflammatory cytokines directly affect the BBB and CNS. This process compromises brain structures and functions involved in mood regulation by disrupting multiple neurophysiological mechanisms.The studies gathered in this Research Topic reinforce that chronic inflammation and neuroimmune dysfunction play a central role in the pathophysiology of depression, actively contributing from symptom onset to the development of treatment resistance.Although the randomized controlled trial evaluating adjunctive low-dose naltrexone did not demonstrate statistically significant superiority over placebo, its findings provide valuable clinical insights for advancing immunomodulatory strategies. The outcome of this investigation underscores an urgent need in contemporary biological psychiatry: the development of more targeted and personalized therapeutic approaches based on the specific neuroinflammatory profiles of individual patients.Ultimately, the future management of major depressive disorder will depend on our ability to precisely modulate neuroimmune communication pathways and mitigate peripheral inflammation, thereby opening more effective avenues to alleviate depressive symptoms and restore patients' quality of life.
